None listed
Conditions
Interventions
Drug : Both the investigational and control groups will receive conventional standard of care (SOC) for heart failure, including loop diuretics, MRAs, and SGLT2i. For both groups, the administration o
Sponsors
The Catholic University of Korea, Daejeon St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age more than 19 years old 2. right ventricular malfunction confirmed with EKG data or cardiac MRI 3. chronic heart failure with LVEF1000, NTproBNP >1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics) 6. Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram 7. Subject who provided voluntary informed consent to participate in the study 8. Patients who have not been administered vericiguat within the last 6 months
Exclusion criteria
Exclusion criteria: 1.Patients with a systolic blood pressure (SBP) < 100 mmHg 2.Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors 3.Moderate-to-severe right ventricular (RV) failure requiring surgical intervention 4. Patients who are currently pregnant or of childbearing potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NTproBNP;Echocardiographic parameters of right ventricular function | — |
Secondary
| Measure | Time frame |
|---|---|
| Kansas City Cardiomyopathy Questionnaire-12; KCCQ-12;6 minuets walk test;major adverse cardiovascular events;Creatinine | — |
Countries
Korea, Republic of
Contacts
Public ContactDahyeon Lee
The Catholic University of Korea, Daejeon St. Mary's Hospital
Outcome results
None listed